{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:40:25Z","timestamp":1770295225734,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"vor","delay-in-days":733,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.rmed.2011.04.002","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T01:04:33Z","timestamp":1304903073000},"page":"1523-1530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Premature discontinuation during the UPLIFT study"],"prefix":"10.1016","volume":"105","author":[{"given":"Marc","family":"Decramer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Molenberghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dacheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartolome","family":"Celli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kesten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Lystig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2011.04.002_bib1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(98)10019-3","article-title":"Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial","author":"Vestbo","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2011.04.002_bib2","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"New Eng J Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2011.04.002_bib4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","article-title":"Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease","volume":"343","author":"The Lung Health Study Research Group","year":"2000","journal-title":"N Eng J Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2011.04.002_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Eng J Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"Am J Respire Crit Care Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-147-9-200711060-00009","article-title":"Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline","volume":"147","author":"Wilt","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/biostatistics\/kxh001","article-title":"Analyzing incomplete longitudinal clinical trial data","volume":"5","author":"Molenberghs","year":"2004","journal-title":"Biostatistics"},{"key":"10.1016\/j.rmed.2011.04.002_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1183\/09031936.00103008","article-title":"Lung function decline in COPD trials: bias from regression to the mean","volume":"32","author":"Suissa","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.04.002_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/ajrccm.178.10.1090b","article-title":"Methodologic shortcomings of the INSPIRE randomized trial","volume":"178","author":"Suissa","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1164\/rccm.200805-721ED","article-title":"Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs","volume":"178","author":"Suissa","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.00108308","article-title":"Exacerbations and intent-to-treat analyses in randomised trials","volume":"32","author":"Suissa","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.04.002_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/thx.2007.082636","article-title":"Canadian Thoracic Society\/Canadian respiratory clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials","volume":"63","author":"Aaron","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.04.002_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1081\/COPD-200026934","article-title":"Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial","volume":"1","author":"Decramer","year":"2004","journal-title":"J COPD"},{"key":"10.1016\/j.rmed.2011.04.002_bib18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2011.04.002_bib19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/ajrccm.152.3.7663792","article-title":"Standardization of spirometry-1994 update","volume":"152","author":"American Thoracic Society","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib20","series-title":"Fundamentals of biostatistics","author":"Rosner","year":"2000"},{"key":"10.1016\/j.rmed.2011.04.002_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-143-5-200509060-00007","article-title":"Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial","volume":"143","author":"Niewoehner","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2011.04.002_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1740774507087703","article-title":"Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation","volume":"5","author":"Greenland","year":"2008","journal-title":"Clin Trials"},{"key":"10.1016\/j.rmed.2011.04.002_bib23","first-page":"1339","article-title":"Intention-to-treat principle","volume":"165","author":"Montori","year":"2001","journal-title":"CMAJ"},{"key":"10.1016\/j.rmed.2011.04.002_bib24","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1378\/chest.124.4.1350","article-title":"Withdrawal from treatment as an outcome in the ISOLDE study of COPD","volume":"124","author":"Calverley","year":"2003","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611111001144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611111001144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:14:11Z","timestamp":1760613251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611111001144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0954611111001144"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2011.04.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Premature discontinuation during the UPLIFT study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2011.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}